Ju Hyun Oh

Dr. Ju Hyun Oh

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
JOJu Hyun Oh
Ju Hyun Oh
HCHong S. Cho
Hong S. Cho
HHHee S. Hwang
Hee S. Hwang
Wonjun JiWonjun Ji
Wonjun Ji
Primary pulmonary meningioma (PPM) is a very rare and mostly benign disease. Although PPM is incidentally detected as a solitary pulmonary nodule on X-ray or chest computed tomography, it does not have unique radiological characteristics; thus, it is difficult to differentiate it from other lung tumors. A healthy 54-year-old man visited our hospital because of multiple variable-sized lung nodules. He had no contributive medical history and no abnormality that was suggestive of extrapulmonary malignancy. Video-assisted thoracoscopic wedge resection was undertaken for diagnosis, and the tumor cells were histopathologically confirmed as PPM. Brain magnetic resonance imaging revealed no intracranial tumor. The patient has been well and without any progression of the remaining lesions over 24 months. Here, we present the clinicopathological features of this case in which the patient's nodules were mistaken for multiple metastatic lung nodules.

23 December 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
JJJong Hwan Jeong
Jong Hwan Jeong
HPHyeongbin Park
Hyeongbin Park
CCChang-Min Choi
Chang-Min Choi
JOJu Hyun Oh
Ju Hyun Oh
GLGeun Dong Lee
Geun Dong Lee
Wonjun JiWonjun Ji
Wonjun Ji
Background: Electromagnetic navigation bronchoscopy (ENB)‐guided transbronchial dye marking and video‐assisted thoracoscopic surgery (VATS) is an emerging technique that enables successful resection of multiple small subsolid pulmonary nodules. The aim of this study was to evaluate the accuracy and safety of preoperative ENB‐guided transbronchial multiple dye localization for VATS resection of subsolid pulmonary nodules.Methods: As a single‐center pilot study, we recruited patients with at least two small or subsolid pulmonary nodules. Multiple‐dye localization was performed by intraoperative ENB‐guided transbronchial injection of an indigo carmine dye. The patients underwent VATS for sublobar resection immediately after localization. The accuracy of ENB‐guided dye marking was checked.Results: ENB‐guided one‐stage multiple dye localization was conducted for 18 pulmonary nodules in seven patients between September 2018 and December 2019. The mean diameter of the pulmonary nodules was 9.3 mm (range, 4–18) and the mean distance from the pleura to pulmonary nodule was 6 mm (range, 1–17 mm). ENB‐guided transbronchial multiple dye localization was successfully performed in 94.4% (17/18), and the accuracy of ENB‐guided dye marking was 88.2% (15/17). When two nodules were not seen in intraoperative fields, anatomical sublobar resection was performed. There was no conversion to thoracotomy and operative mortalities. Among the seven patients, only one patient showed mild intrabronchial bleeding but stopped spontaneously. The changes in lung function after multiple wedge resections (−1.6% to 24.8%) were tolerable level.Conclusions: ENB‐guided one‐stage transbronchial dye localization showed accurate and safe intraoperative identification of multiple subsolid pulmonary nodules. A large scale prospective clinical study is warranted.

21 March 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
JOJu Hyun Oh
Ju Hyun Oh
CCChang-Min Choi
Chang-Min Choi
SKSeulgi Kim
Seulgi Kim
WKWoo Sung Kim
Woo Sung Kim
HHHee Sang Hwang
Hee Sang Hwang
Wonjun JiWonjun Ji
Wonjun Ji
Background: Electromagnetic navigation bronchoscopy (ENB) is a useful method to obtain tissue for peripheral lung nodules. We aimed to understand the diagnostic yield and safety profile in high‐risk pulmonary nodules that cannot be accessed by percutaneous transthoracic needle biopsy.Methods: In this single‐center retrospective study, we reviewed patients who underwent ENB for high‐risk pulmonary nodules. All procedures were performed under moderate sedation using intravenous midazolam and fentanyl.Results: A total of 100 pulmonary nodules in 90 patients were subjected to ENB between October 2018 and May 2020. The median age of the study population was 66 (59–73). The mean diameter of the lung nodules was 27.9 mm. The diagnostic yield of ENB‐guided biopsy was 53.0%. Although the nodule size (odds ratio: 1.055, p = 0.007) and positive bronchus sign (odds ratio: 2.918, p = 0.020) were associated with the diagnostic yield during univariate analysis, nodule size was the only independent variable on the multivariable analysis. Interestingly, the diagnostic yield showed an upward trend after 60 cases, from 45%–65%. Procedure‐related complications were reported in 16 cases; among these, pneumothorax occurred in three cases, and four cases experienced moderate bleeding. No instance of major bleeding or death was linked to ENB‐guided biopsy.Conclusion: ENB‐guided biopsy for high‐risk pulmonary nodules demonstrated an acceptable diagnostic yield and good safety profile. Moreover, the diagnostic yield was associated with nodule size and procedure experience.

9 August 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
JOJu Hyun Oh
Ju Hyun Oh
CCChang-Min Choi
Chang-Min Choi
SKSeulgi Kim
Seulgi Kim
SJSe Jin Jang
Se Jin Jang
SOSang Young Oh
Sang Young Oh
Wonjun JiWonjun Ji
Wonjun Ji
Electromagnetic navigation bronchoscopy (ENB) is an emerging technique used to evaluate peripheral lung lesions. The aim of this study was to determine the diagnostic yield, safety profile, and adequacy of specimens obtained using ENB for molecular testing. This single-center, prospective pilot study recruited patients with peripheral pulmonary nodules that were not suitable for biopsy via percutaneous transthoracic needle biopsy methods. The possibility of molecular testing, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and programmed death ligand 1 (PD-L1), was identified with non-small cell lung cancer (NSCLC) tissue obtained using ENB. ENB-guided biopsy was performed on 30 pulmonary nodules in 30 patients. ENB-guided biopsy was successfully performed in 96.6% (29/30) of cases, but one case failed to approach the target lesion. The diagnostic accuracy of ENB-guided biopsy was 68.0% (17/25). Biopsy-related pneumothorax occurred in one patient and there was no major bleeding or deaths related to the procedure. Among 13 patients diagnosed with NSCLC, molecular testing was successfully performed in 92.3% (12/13). ENB-guided biopsy demonstrated acceptable accuracy and excellent sample adequacy, with a high possibility of achieving molecular testing and a good safety profile to evaluate peripheral pulmonary nodules, even when the percutaneous approach was difficult and/or dangerous.

15 December 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HPHyeonjung Park
Hyeonjung Park
MJMinseol Jang
Minseol Jang
DKDaehyun Kim
Daehyun Kim
CKChul Kim
Chul Kim
JSJun Hyeong Song
Jun Hyeong Song
HSHae Sun Suh
Hae Sun Suh
Background: Pulmonary rehabilitation, a nonpharmacological treatment for chronic respiratory diseases, is underused due to limited access and time constraints. In a randomized controlled trial, the digital therapeutics (DTx) demonstrated superior efficacy to standard treatment. However, evidence on the cost-effectiveness of DTx and appropriate pricing strategies remains limited. Objective: This study aimed to evaluate the cost-effectiveness of DTx through cost-utility analysis and to explore a value-based price for its implementation. Methods: An economic evaluation was based on an 8-week randomized controlled trial involving 84 participants assigned to either the DTx group or standard treatment group. Costs were estimated from a health care system perspective. Quality-adjusted life years (QALYs) were estimated by using mapping algorithms from the chronic obstructive pulmonary disease assessment test to EQ-5D-3L. Cost-utility analysis was conducted to estimate the incremental cost-utility ratio (ICUR), which represents the additional cost per QALY gained. The willingness-to-pay threshold was set at US $19,410 per QALY. Sensitivity analyses included probabilistic sensitivity analysis, deterministic sensitivity analysis, and subgroup and scenario analyses, including a 1-year Markov model. Results: Compared with standard treatment, DTx increased QALY by 0.0096 at an additional cost of US $85.33, resulting in an ICUR of US $8890 per QALY gained. The maximum value-based price for an 8-week DTx program was estimated at US $192. In probabilistic sensitivity analysis, DTx had a 60.2% probability of being cost-effective at the set willingness-to-pay threshold, with 88.6% of iterations in the northeast quadrant falling below the threshold. The deterministic sensitivity analysis showed that ICURs remained below the willingness-to-pay threshold under all tested assumptions, with the maximum ICUR (US $15,644/QALY) also staying below the threshold. Subgroup analysis confirmed cost-effectiveness in both older adults (≥65 y) and non–older adults (<65 y) populations, and in both chronic obstructive pulmonary disease and interstitial lung disease groups. The 1-year Markov model estimated an ICUR of US $4398 per QALY. Conclusions: DTx for pulmonary rehabilitation demonstrated the cost-effectiveness compared with standard treatment. These findings support its potential for improving outcomes in patients with chronic respiratory disease and provide a pricing framework to facilitate its integration into health care systems.

1 April 2025 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
JOJu Hyun Oh
Ju Hyun Oh
JLJae Ha Lee
Jae Ha Lee
SCSung Jun Chung
Sung Jun Chung
YLYoung Seok Lee
Young Seok Lee
TKTae-Hyung Kim
Tae-Hyung Kim
OGon behalf of Korean Interstitial Lung Diseases Study Group
on behalf of Korean Interstitial Lung Diseases Study Group
Connective tissue disease (CTD), comprising a range of autoimmune disorders, is often accompanied by lung involvement, which can lead to life-threatening complications. The primary types of CTDs that manifest as interstitial lung disease (ILD) include rheumatoid arthritis, systemic sclerosis, Sjögren’s syndrome, mixed CTD, idiopathic inflammatory myopathies, and systemic lupus erythematosus. CTD-ILD presents a significant challenge in clinical diagnosis and management due to its heterogeneous nature and variable prognosis. Early diagnosis through clinical, serological, and radiographic assessments is crucial for distinguishing CTD-ILD from idiopathic forms and for implementing appropriate therapeutic strategies. Hence, we have reviewed the multiple clinical manifestations and diagnostic approaches for each type of CTD-ILD, acknowledging the diversity and complexity of the disease. The importance of a multidisciplinary approach in optimizing the management of CTD-ILD is emphasized by recent therapeutic advancements, which include immunosuppressive agents, antifibrotic therapies, and newer biological agents targeting specific pathways involved in the pathogenesis. Therapeutic strategies should be customized according to the type of CTD, the extent of lung involvement, and the presence of extrapulmonary manifestations. Additionally, we aimed to provide clinical guidance, including therapeutic recommendations, for the effective management of CTD-ILD, based on patient, intervention, comparison, outcome (PICO) analysis.